← Leaderboards
Peter A Gottlieb
University Of Colorado Denver
$9,273,760
Attributed
$9,273,760
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$9,273,760 · 18
By mechanism
U01$7,379,037 · 2
R01$1,044,264 · 1
R21$692,598 · 1
M01$157,861 · 14
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- George S Eisenbarth$13,354,570
- Marian J. Rewers$53,889,410
- Aaron W Michels$8,254,447
- Alexander C Wiseman$708,682
- H Peter Chase$5,128,701
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyAutoimmune DiseasesDiabetes MellitusHuman SubjectC-PeptideT-LymphocyteProtocols DocumentationFundingDiagnosisPreventionImmunePreventInsulinProductivityInsulin-Dependent Diabetes MellitusFutureClinical ResearchPopulations At RiskDietary InterventionInsulin Dependent Diabetes MellitusRecruitment ActivityAutoantibodiesRandomizedDiabetes Mellitus, Insulin-Dependent
Grant awards (36)
TrialNet: Diabetes Type 1 Prevention$673,074
U01 · FY2018 · DK · contact PI
TrialNet: Diabetes Type 1 Prevention$587,157
U01 · FY2017 · DK · contact PI
TrialNet: Diabetes Type 1 Prevention$587,158
U01 · FY2016 · DK · contact PI
TrialNet: Diabetes Type 1 Prevention$587,158
U01 · FY2015 · DK · contact PI
TrialNet: Diabetes Type 1 Prevention$604,774
U01 · FY2014 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$8,386
U01 · FY2014 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$547,994
U01 · FY2013 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$397,803
U01 · FY2012 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$612,812
U01 · FY2011 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$608,449
U01 · FY2010 · DK · contact PI
Trainet: Diabetes Type 1 Prevention$568,659
U01 · FY2009 · DK · contact PI
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$356
M01 · FY2008 · RR · contact PI
EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS$119
M01 · FY2008 · RR · contact PI
TrialNet: Diabetes Type 1 Prevention Trial$993,520
U01 · FY2007 · DK · contact PI
TRIALNET NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES$44,661
M01 · FY2007 · RR · contact PI
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$15,134
M01 · FY2007 · RR · contact PI
TREATMENT WITH HOKT3YL (ALA-ALA) IN TYPE 1 DIABETES MELLITUS$14,397
M01 · FY2007 · RR · contact PI
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$3,030
M01 · FY2007 · RR · contact PI
EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS$1,010
M01 · FY2007 · RR · contact PI
DPT-1 / TrialNet$183,094
U01 · FY2006 · DK · contact PI
TRIALNET NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES$39,966
M01 · FY2006 · RR · contact PI
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$19,982
M01 · FY2006 · RR · contact PI
STUDY 1: TO COMPARE THE RELIABILITY OF MMT AND IV GLUCAGON STIMULATION TEST$1,620
M01 · FY2006 · RR · contact PI
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$928
M01 · FY2006 · RR · contact PI
LONG-TERM EFFECTS OF NBI 6024 IN TYPE 1 DIABETES SUBJECTS FROM NBI602-0003 TRIAL$309
M01 · FY2006 · RR · contact PI
DPT-1 / TrialNet$418,999
U01 · FY2005 · DK
LONG-TERM EFFECTS OF NBI 6024 IN TYPE 1 DIABETES SUBJECTS FROM NBI602-0003 TRIAL$6,005
M01 · FY2005 · RR
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES$2,153
M01 · FY2005 · RR
Long-Term Effect of NBI 6024 in Type 1 Diabetes Subjects$8,191
M01 · FY2004 · RR
Human TCR/HLA Transgenic Mice to Prevent T1DM$338,959
R21 · FY2003 · DK
Human TCR/HLA Transgenic Mice to Prevent T1DM$79,581
R21 · FY2003 · DK
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES$313,680
R01 · FY2002 · DK
Human TCR/HLA Transgenic Mice to Prevent T1DM$274,058
R21 · FY2002 · DK
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES$330,720
R01 · FY2001 · DK
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES$25,000
R01 · FY2001 · DK
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES$374,864
R01 · FY2000 · DK